Search results
Results from the WOW.Com Content Network
The side effects of bicalutamide, a nonsteroidal antiandrogen (NSAA), including its frequent and rare side effects, have been well-studied and characterized. The most common side effects of bicalutamide monotherapy in men include breast tenderness , breast growth , feminization , demasculinization , and hot flashes .
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Common (1–10%) General and psychiatric disorders • Asthenia • Decreased libido • Erectile dysfunction • Hot flashes: Skin and subcutaneous tissue disorders • Decreased body hair: Hepato-biliary disorders • Elevated liver enzymes [b] Uncommon (0.1–1%) Immune system disorders and hypersensitivity reactions • Angioedema • Hives
Another large study reported a rate of impotence of only 9.3% with bicalutamide relative to 6.5% for standard care (the controls), a rate of decreased libido of only 3.6% with bicalutamide relative to 1.2% for standard care, and a rate of 9.2% with bicalutamide for hot flashes relative to 5.4% for standard care. [125]
[2] [254] At 37 °C (98.6 °F), or normal human body temperature, bicalutamide is practically insoluble in water (4.6 mg/L), acid (4.6 mg/L at pH 1), and alkali (3.7 mg/L at pH 8). [ 27 ] [ 89 ] In organic solvents , it is slightly soluble in chloroform and absolute ethanol , sparingly soluble in methanol , and freely soluble in acetone and ...
Footnotes: a = Phase III studies of combined androgen blockade (bicalutamide or flutamide + GnRH agonist) in men with advanced prostate cancer. b = Incidence >5% regardless of causality . c = 250 mg three times per day at 8-hour intervals.
Bicalutamide (Casodex): Marketed for the treatment of prostate cancer and also used in the treatment of hirsutism in women, [4] as a component of hormone therapy for transgender women, [5] to delay precocious puberty in boys, [7] to prevent or alleviate priapism, [8] and for other indications.
[19] [20] [21] The median age of the patients was 73.5 years (range 59 to 91 years), and median duration of bicalutamide exposure was 7.5 weeks (range 1 to 312 weeks). [19] Cases of interstitial pneumonitis have also been reported in association with flutamide , nilutamide , and gonadotropin-releasing hormone (GnRH) agonists .